{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:40:09Z","timestamp":1750495209019,"version":"3.41.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020865","name":"Takeda Pharma Vertrieb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12325-025-03210-x","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T07:39:25Z","timestamp":1747899565000},"page":"3419-3436","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Number and Treatment Patterns in Cytomegalovirus Viremia and Disease Following Solid Organ and Hematopoietic Stem Cell Transplantation in Germany: Results of a Delphi Consensus Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Daniel","family":"Teschner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7879-9287","authenticated-orcid":false,"given":"Jana","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Piehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tino","family":"Schubert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"3210_CR1","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1186\/s12913-014-0534-0","volume":"14","author":"R Attieh","year":"2014","unstructured":"Attieh R, Gagnon MP, Estabrooks CA, L\u00e9gar\u00e9 F, Ouimet M, Vazquez P, Nuno R. Organizational readiness for knowledge translation in chronic care: a Delphi study. BMC Health Serv Res. 2014;14:534.","journal-title":"BMC Health Serv Res"},{"issue":"4","key":"3210_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/cid\/ciab988","volume":"75","author":"RK Avery","year":"2022","unstructured":"Avery RK, Alain S, Alexander BD, Blumberg EA, Chemaly RF, Cordonnier C, Duarte RF, Florescu DF, Kamar N, Kumar D, Maertens J, Marty FM, Papanicolaou GA, Silveira FP, Witzke O, Wu J, Sundberg AK, Fournier M, SOLSTICE Trial Investigators. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clin Infect Dis. 2022;75(4):690\u2013701.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"3210_CR3","doi-asserted-by":"publisher","first-page":"882","DOI":"10.6004\/jnccn.2016.0093","volume":"14","author":"LR Baden","year":"2016","unstructured":"Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, Cooper B, Dubberke ER, Engemann AM, Freifeld AG, Greene JN, Ito JI, Kaul DR, Lustberg ME, Montoya JG, Rolston K, Satyanarayana G, Segal B, Seo SK, Shoham S, Taplitz R, Topal J, Wilson JW, Hoffmann KG, Smith C. Prevention and treatment of cancer-related infections, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(7):882\u2013913.","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"3210_CR4","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1177\/135965350901400512","volume":"14","author":"G Boivin","year":"2009","unstructured":"Boivin G, Goyette N, Rollag H, Jardine AG, Pescovitz MD, Asberg A, Ives J, Hartmann A, Humar A. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther. 2009;14(5):697\u2013704.","journal-title":"Antivir Ther"},{"issue":"6","key":"3210_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13754","volume":"23","author":"R Charlotte","year":"2021","unstructured":"Charlotte R, Fran\u00e7ois P, Jonathan M, V\u00e9ronique B, Olivier B, Tristan D, S\u00e9verine F, J\u00e9r\u00f4me L, Adrien T, Claire D, Esp\u00e9rie B, Eve C, Antoine R. Use of anti-CMV immunoglobulins in lung transplant recipients: the French experience. Transpl Infect Dis. 2021;23(6): e13754.","journal-title":"Transpl Infect Dis"},{"issue":"11","key":"3210_CR6","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/ijms20112666","volume":"20","author":"SY Cho","year":"2019","unstructured":"Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: current status and future immunotherapy. Int J Mol Sci. 2019;20(11):2666.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3210_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3138\/cjpe.020.005","volume":"20","author":"CA Christie","year":"2005","unstructured":"Christie CA, Barela E. The Delphi Technique as a method for increasing inclusion in the evaluation process. Can J Program Eval. 2005;20(1):105\u201322.","journal-title":"Can J Program Eval"},{"key":"3210_CR8","unstructured":"Deutsche Stiftung Organtransplantation. Jahresbericht Deutsche Stiftung Organtransplantation (DSO) 2021. 2022. https:\/\/dso.de\/SiteCollectionDocuments\/DSO-Jahresbericht%202021.pdf."},{"key":"3210_CR9","unstructured":"Deutsches Register f\u00fcr Stammzelltransplantationen. Jahresbericht 2021 Deutsches Register Stammzelltransplantationen (DRST). 2022. https:\/\/www.drst.de\/drst\/download\/jb2021.pdf."},{"issue":"8","key":"3210_CR10","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.3390\/jcm9082352","volume":"9","author":"C Engelmann","year":"2020","unstructured":"Engelmann C, Sterneck M, Weiss KH, Templin S, Zopf S, Denk G, Eurich D, Pratschke J, Weiss J, Braun F, Welker MW, Zimmermann T, Knipper P, Nierhoff D, Lorf T, J\u00e4ckel E, Hau HM, Tsui TY, Perrakis A, Schlitt HJ, Herzer K, Tacke F. Prevention and management of CMV infections after liver transplantation: current practice in german transplant centers. J Clin Med. 2020;9(8):2352.","journal-title":"J Clin Med"},{"issue":"4","key":"3210_CR11","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.transproceed.2014.11.066","volume":"47","author":"H Eshraghi","year":"2015","unstructured":"Eshraghi H, Hekmat R. Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients? Transplant Proc. 2015;47(4):1136\u20139.","journal-title":"Transplant Proc"},{"issue":"Suppl 1","key":"3210_CR12","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/infdis\/jiz454","volume":"221","author":"G Haidar","year":"2020","unstructured":"Haidar G, Boeckh M, Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221(Suppl 1):S23\u201331.","journal-title":"J Infect Dis"},{"issue":"3","key":"3210_CR13","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1002\/jmv.21996","volume":"83","author":"P Halfon","year":"2011","unstructured":"Halfon P, Berger P, Khiri H, Martineau A, P\u00e9naranda G, Merlin M, Faucher C. Algorithm based on CMV kinetics DNA viral load for preemptive therapy initiation after hematopoietic cell transplantation. J Med Virol. 2011;83(3):490\u20135.","journal-title":"J Med Virol"},{"issue":"14","key":"3210_CR14","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.7150\/ijms.62621","volume":"18","author":"SH Han","year":"2021","unstructured":"Han SH, Yoo SG, Do Han K, La Y, Kwon DE, Lee KH. The incidence and effect of cytomegalovirus disease on mortality in transplant recipients and general population: real-world nationwide cohort data. Int J Med Sci. 2021;18(14):3333\u201341. https:\/\/doi.org\/10.7150\/ijms.62621.","journal-title":"Int J Med Sci"},{"issue":"12","key":"3210_CR15","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/jac\/dkq368","volume":"65","author":"S Hantz","year":"2010","unstructured":"Hantz S, Garnier-Geoffroy F, Mazeron MC, Garrigue I, Merville P, Mengelle C, Rostaing L, Saint Marcoux F, Essig M, Rerolle JP, Cotin S, Germi R, Pillet S, Lebranchu Y, Turlure P, Alain S. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother. 2010;65(12):2628\u201340.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3210_CR16","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/jmv.23539","volume":"85","author":"H Harvala","year":"2013","unstructured":"Harvala H, Stewart C, Muller K, Burns S, Marson L, MacGilchrist A, Johannessen I. High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy. J Med Virol. 2013;85(5):893\u20138.","journal-title":"J Med Virol"},{"key":"3210_CR17","unstructured":"Institute for Hospital Remuneration Systems (InEK) GmbH. Age classes HSCT in Germany 2021 from the InEK Data Browser. 2022. www.g-drg.de."},{"issue":"1","key":"3210_CR18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1007\/s12185-021-03218-3","volume":"115","author":"F Jinnouchi","year":"2022","unstructured":"Jinnouchi F, Mori Y, Yoshimoto G, Yamauchi T, Nunomura T, Yurino A, Hayashi M, Yuda J, Shima T, Odawara J, Takashima S, Kamezaki K, Kato K, Miyamoto T, Akashi K, Takenaka K. Incidence of refractory cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022;115(1):96\u2013106.","journal-title":"Int J Hematol"},{"issue":"6","key":"3210_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/QCO.0000000000000607","volume":"32","author":"F Khawaja","year":"2019","unstructured":"Khawaja F, Batista MV, El Haddad L, Chemaly RF. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr Opin Infect Dis. 2019;32(6):565\u201374.","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"3210_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12881","volume":"20","author":"SJ Kim","year":"2018","unstructured":"Kim SJ, Huang YT, Foldi J, Lee YJ, Maloy M, Giralt SA, Jakubowski AA, Papanicolaou GA. Cytomegalovirus resistance in CD34+-selected hematopoietic cell transplant recipients. Transpl Infect Dis. 2018;20(3): e12881.","journal-title":"Transpl Infect Dis"},{"issue":"7","key":"3210_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0200267","volume":"13","author":"R Lachmann","year":"2018","unstructured":"Lachmann R, Loenenbach A, Waterboer T, Brenner N, Pawlita M, Michel A, Thamm M, Poethko-M\u00fcller C, Wichmann O, Wiese-Posselt M. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. PLoS ONE. 2018;13(7): e0200267.","journal-title":"PLoS ONE"},{"issue":"12","key":"3210_CR22","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1097\/TP.0b013e31828ee12e","volume":"95","author":"AK Le Page","year":"2013","unstructured":"Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation. 2013;95(12):1455\u201360.","journal-title":"Transplantation"},{"key":"3210_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9106","author":"AP Limaye","year":"2023","unstructured":"Limaye AP, Budde K, Humar A, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023. https:\/\/doi.org\/10.1001\/jama.2023.9106. (Published online June 06, 2023).","journal-title":"JAMA"},{"issue":"14","key":"3210_CR24","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1182\/bloodadvances.2024012922","volume":"8","author":"RY Lin","year":"2024","unstructured":"Lin RY, Anderson AD, Natori Y, Raja M, Morris MI, Jimenez AJ, et al. Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy. Blood Adv. 2024;8(14):3813\u201322.","journal-title":"Blood Adv"},{"key":"3210_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64:87\u201391.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"3210_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciae321","volume":"79","author":"P Ljungman","year":"2024","unstructured":"Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, et al. Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum. Clin Infect Dis. 2024;79(3):787\u201394.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3210_CR27","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","volume":"19","author":"P Ljungman","year":"2019","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN, 2017 European Conference on Infections in Leukaemia Group. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260\u201372.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"3210_CR28","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/CMR.00062-12","volume":"26","author":"S Manicklal","year":"2013","unstructured":"Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The silent global burden of congenital cytomegalovirus. Clin Microbiol Rev. 2013;26(1):86\u2013102. https:\/\/doi.org\/10.1128\/CMR.00062-12.","journal-title":"Clin Microbiol Rev"},{"issue":"4","key":"3210_CR29","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1684\/ejd.2022.4272","volume":"32","author":"I Martinez-Saguer","year":"2022","unstructured":"Martinez-Saguer I, Dominas N, Straben U, Greve J, Brehler R, Magerl M, Knipps LM, Knop J, Flemming A, Schubert T, Maurer M. Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study. Eur J Dermatol. 2022;32(4):487\u201394.","journal-title":"Eur J Dermatol"},{"issue":"8","key":"3210_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fpubh.2020.00457","volume":"2020","author":"M Niederberger","year":"2020","unstructured":"Niederberger M, Spranger J. Delphi technique in health sciences: a map. Front Public Health. 2020;2020(8):457.","journal-title":"Front Public Health"},{"issue":"6","key":"3210_CR31","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/tid.12447","volume":"17","author":"RR Razonable","year":"2015","unstructured":"Razonable RR, Blumberg EA. It\u2019s not too late: a proposal to standardize the terminology of \u201clate-onset\u201d cytomegalovirus infection and disease in solid organ transplant recipients. Transpl Infect Dis. 2015;17(6):779\u201384.","journal-title":"Transpl Infect Dis"},{"key":"3210_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512","volume":"33","author":"RR Razonable","year":"2019","unstructured":"Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients\u2014guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33: e13512.","journal-title":"Clin Transplant"},{"issue":"4","key":"3210_CR33","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/infdis\/jit475","volume":"209","author":"E Shmueli","year":"2014","unstructured":"Shmueli E, Or R, Shapira MY, Resnick IB, Caplan O, Bdolah-Abram T, Wolf DG. High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation. J Infect Dis. 2014;209(4):557\u201361.","journal-title":"J Infect Dis"},{"key":"3210_CR34","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s15010-022-01847-2","volume":"50","author":"D Teschner","year":"2022","unstructured":"Teschner D, Knop J, Piehl C, Junker S, Witzke O. Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data. Infection. 2022;50:1543\u201355 (Epub ahead of print).","journal-title":"Infection"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03210-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03210-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T08:14:15Z","timestamp":1750493655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03210-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["3210"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03210-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"9 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Daniel Teschner has received research grants from Gilead, honoraria from and served as a consultant to AbbVie, BioNTech, Gilead, iQone, Jazz, Mikrogen, MSD, Noscendo, Octapharma, Pfizer, Tillotts, and Takeda, honoraria from AstraZeneca, F2G, Janssen, Novartis, and Sanofi, and travel grants from AbbVie, Astellas, Celgene, Gilead, Jazz, Medac, MSD, and Tillotts. Jana Knop and Christian Piehl are employees of Takeda Pharma Vertrieb GmbH & Co.\u00a0KG.\u00a0Christian Piehl holds Takeda stocks. Tino Schubert is owner and employee of LinkCare GmbH, which received consulting honoraria from Takeda Pharma Vertrieb GmbH and Mallinckrodt Pharmaceuticals. Oliver Witzke received research grants for clinical studies, speaker\u2019s fees, honoraria, and travel expenses from Alexion, Amgen, Astellas, Basilea, Biotest, Bristol Myers Squibb, Chiesi, Correvio, Gilead, Hexal, Janssen, Dr. F. K\u00f6hler Chemie, MSD, Novartis, Pfizer, Roche, Sanofi, Takeda, Teva, and UCB, as well as an unrestricted grant from the Rudolf-Ackermann-Stiftung (Stiftung f\u00fcr Klinische Infektiologie).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Participants were fully informed about the study\u2019s objectives and the intent to publish the results. Consent was given voluntarily through signed contracts. Participant answers were anonymized, and no communication occurred between them during the study. Data protection adhered to GDPR regulations, with analyses conducted pseudonymously to ensure privacy. Ethical committee consultation was unnecessary as the study only involved physician responses, with no patient information and no interference with personal integrity.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}